Clinical Outcomes and Cost Comparisons of Stent and Non-Stent Interventions in Infrainguinal Peripheral Artery Disease: Insights From the Excellence in Peripheral Artery Disease (XLPAD) Registry.


Journal

The Journal of invasive cardiology
ISSN: 1557-2501
Titre abrégé: J Invasive Cardiol
Pays: United States
ID NLM: 8917477

Informations de publication

Date de publication:
01 2019
Historique:
entrez: 6 1 2019
pubmed: 6 1 2019
medline: 18 12 2019
Statut: ppublish

Résumé

The contemporary limb outcomes and costs of stent-based vs non-stent based strategies in endovascular revascularization of femoropopliteal (FP) peripheral artery disease (PAD) are not well understood. We present data from the ongoing United States multicenter Excellence in Peripheral Artery Disease Registry between 2006-2016 to compare stent vs non-stent treatment outcomes and associated costs in FP interventions. A total of 2910 FP interventions were performed in 2162 patients (mean age, 66 years), comprising 1339 stent based (superficial femoral artery, 93%) in 1007 patients and 1571 non-stent interventions (superficial femoral artery, 85%) in 1155 patients. A growing trend for non-stent based interventions and a declining trend in repeat revascularization rate at 1 year were observed across years of registry enrollment. Stent implantation was the prevailing strategy in treating longer FP lesions (mean length, 152 mm vs 105 mm; P<.001) and chronic total occlusions (65% vs 40%; P<.001), while stent implantation was employed less frequently when treating in-stent restenotic lesions (14% vs 20%; P<.001). Stent and non-stent interventions had similar 1-year limb outcomes in all-cause death, target-limb revascularization, target-vessel revascularization, and major or minor amputation. The average procedure costs for the stent group were significantly higher than the non-stent group ($6215 vs $4790; P<.001). There is a growing trend for non-stent FP artery interventions, with a significant decline in 1-year target-limb revascularization rates over time. One-year limb outcomes in stent-based compared to non-stent interventions are similar; however, at a significantly higher procedural cost.

Sections du résumé

BACKGROUND
The contemporary limb outcomes and costs of stent-based vs non-stent based strategies in endovascular revascularization of femoropopliteal (FP) peripheral artery disease (PAD) are not well understood.
METHODS AND RESULTS
We present data from the ongoing United States multicenter Excellence in Peripheral Artery Disease Registry between 2006-2016 to compare stent vs non-stent treatment outcomes and associated costs in FP interventions. A total of 2910 FP interventions were performed in 2162 patients (mean age, 66 years), comprising 1339 stent based (superficial femoral artery, 93%) in 1007 patients and 1571 non-stent interventions (superficial femoral artery, 85%) in 1155 patients. A growing trend for non-stent based interventions and a declining trend in repeat revascularization rate at 1 year were observed across years of registry enrollment. Stent implantation was the prevailing strategy in treating longer FP lesions (mean length, 152 mm vs 105 mm; P<.001) and chronic total occlusions (65% vs 40%; P<.001), while stent implantation was employed less frequently when treating in-stent restenotic lesions (14% vs 20%; P<.001). Stent and non-stent interventions had similar 1-year limb outcomes in all-cause death, target-limb revascularization, target-vessel revascularization, and major or minor amputation. The average procedure costs for the stent group were significantly higher than the non-stent group ($6215 vs $4790; P<.001).
CONCLUSION
There is a growing trend for non-stent FP artery interventions, with a significant decline in 1-year target-limb revascularization rates over time. One-year limb outcomes in stent-based compared to non-stent interventions are similar; however, at a significantly higher procedural cost.

Identifiants

pubmed: 30611122
pmc: PMC6428413
mid: NIHMS1017774

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Subventions

Organisme : CSRD VA
ID : I01 CX000440
Pays : United States
Organisme : CSRD VA
ID : I01 CX001549
Pays : United States
Organisme : CSRD VA
ID : I21 CX000793
Pays : United States

Références

Ann Vasc Surg. 2018 Jan;46:234-240
pubmed: 28602895
JACC Cardiovasc Interv. 2016 Oct 24;9(20):2157-2164
pubmed: 27765312
Circ Cardiovasc Interv. 2017 Sep;10(9):
pubmed: 28916599
J Vasc Interv Radiol. 2017 Dec;28(12):1617-1627.e1
pubmed: 29031986
J Rehabil Res Dev. 2014;51(8):1325-30
pubmed: 25625913
J Endovasc Ther. 2017 Dec;24(6):783-792
pubmed: 28795638
Circulation. 2017 Jun 6;135(23):2218-2226
pubmed: 28424222
Ann Vasc Surg. 2010 Jul;24(5):577-87
pubmed: 20579582
Ann Surg. 2017 Feb;265(2):424-430
pubmed: 28059972
J Invasive Cardiol. 2015 Jan;27(1):14-8
pubmed: 25589695
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
JACC Cardiovasc Interv. 2016 Nov 14;9(21):2243-2252
pubmed: 27832850
Circulation. 2016 Apr 12;133(15):1472-83; discussion 1483
pubmed: 26969758
Catheter Cardiovasc Interv. 2017 Mar 1;89(4):728-734
pubmed: 28239949
J Endovasc Ther. 2016 Oct;23(5):701-7
pubmed: 27193308
Circ Cardiovasc Interv. 2016 Feb;9(2):e002730
pubmed: 26839391
Cardiovasc Intervent Radiol. 2017 Dec;40(12):1832-1838
pubmed: 28948322
Cardiovasc Intervent Radiol. 2015 Aug;38(4):846-54
pubmed: 25962990
J Vasc Surg. 2017 Feb;65(2):495-500
pubmed: 27986487
J Am Coll Cardiol. 2015 Mar 10;65(9):920-7
pubmed: 25744009
Lancet. 2018 Jan 20;391(10117):219-229
pubmed: 29132880

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH